Condition (MeSH)
CHARGE Syndrome
ClinicalTrials.gov lists 5 trials for CHARGE Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with CHARGE Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did CHARGE Syndrome trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2021 | 1 |
| 2018 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are CHARGE Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 1 |
| Observational | 4 |
How many CHARGE Syndrome trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover CHARGE Syndrome? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Experience with cultured thymus tissue in 105 children. | The Journal of allergy and clinical immunology | 2022 | Yes |
| Discovery of a novel CHD7 CHARGE syndrome variant by integrated omics analyses. | American journal of medical genetics. Part A | 2021 | Yes |
| Feeding difficulty is the dominant feature in 12 Chinese newborns with CHD7 pathogenic variants. | BMC medical genetics | 2019 | Yes |
| CHARGE and Kabuki Syndromes: Gene-Specific DNA Methylation Signatures Identify Epigenetic Mechanisms Linking These Clinically Overlapping Conditions. | American journal of human genetics | 2017 | Yes |
| Psychomotor and cognitive impairments of children with CHARGE syndrome: common and variable features. | Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence | 2013 | Yes |
Showing 5 of 8 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| CHARGE syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| CHARGE syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| CHARGE syndrome | Prevalence at birth | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
| CHARGE syndrome | Prevalence at birth | 1-9 / 100 000 | Canada | Not stated | Unspecified |
| CHARGE syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| CHARGE syndrome | 138 | Exact | Orphadata Science knowledge files, Product 1 |
| CHARGE syndrome | 138 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.